GSK is paying $10.6 billion in cash to acquire Nuvalent, a precision oncology company with three investigational therapies targeting non-small cell lung cancer. It is the British pharmaceutical giant’s largest acquisition in over a decade, and a clear signal that new CEO Luke Miels is betting the company’s future on cancer treatments.
Nuvalent shareholders will receive $124 per share, a 40% premium over the company’s last closing price of roughly $88.49. Following the announcement on June 9, Nuvalent’s stock surged nearly 39% in premarket trading, essentially pricing in the deal immediately.
What GSK is actually buying
The crown jewels here are two drugs with names that sound like they were generated by a Scrabble tournament: zidesamtinib and neladalkib. Both are currently under active FDA review and could launch by the end of 2026.
A third investigational therapy rounds out the Nuvalent portfolio, giving GSK a trio of late-stage assets in a single transaction.
